

# Tetyana A Pertseva

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8843525/publications.pdf>

Version: 2024-02-01

32  
papers

91  
citations

2258059

3  
h-index

2550090

3  
g-index

32  
all docs

32  
docs citations

32  
times ranked

76  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma. <i>Respiratory Medicine</i> , 2013, 107, 180-195.   | 2.9 | 45        |
| 2  | Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2016, 29, 346-361.             | 1.4 | 24        |
| 3  | Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate-to-severe asthma: a randomised controlled trial. <i>Current Medical Research and Opinion</i> , 2013, 29, 1357-1369. | 1.9 | 21        |
| 4  | Influence of tobacco-smoking on serum level of transforming growth factor (TGF) beta 1 in COPD patients. , 2017, , .  |     | 1         |
| 5  | Whether there are pharmacoeconomic and other advantages of using procalcitonin-guide antibacterial treatment in patients with severe community-acquired pneumonia in developing countries?. , 2015, , .                                     |     | 0         |
| 6  | Role of matrix metalloproteinase in predicting of COPD stability. , 2015, , .   |     | 0         |
| 7  | Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients. , 2015, , .  |     | 0         |
| 8  | The relationship between dyspnea and detection of depression in COPD patients (pts). , 2015, , .  |     | 0         |
| 9  | Proteinase-inhibitor system state in patients with COPD. , 2015, , .  |     | 0         |
| 10 | Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes. , 2015, , .   |     | 0         |
| 11 | Vascular-platelet hemostasis parameters in the stable phase and in acute exacerbation (AE) of COPD. , 2015, , .   |     | 0         |
| 12 | Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)?. , 2015, , .   |     | 0         |
| 13 | Matrix metalloproteinase, hyaluronic acid and C-reactive protein: Are they really markers of lung obstruction at COPD but not cardiovascular comorbidity?. , 2015, , .  |     | 0         |
| 14 | Myocardial ischemia in patients (pts) with COPD and stable angina during 24-hour ambulatory Holter ECG monitoring. , 2015, , .  |     | 0         |
| 15 | COPD: Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination and oxygen saturation (OS) in patients (pts) with different plasma surfactant protein D (SP-D) level. , 2015, , .                                       |     | 0         |
| 16 | What is the best biomarker of COPD stability?. , 2015, , .  |     | 0         |
| 17 | Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP). , 2015, , .   |     | 0         |
| 18 | Peculiarities of climacteric syndrome in women with bronchial asthma, developed in the perimenopausal period, correction of these disorders. , 2015, , .  |     | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | "Many-armedâ€•CD4: Why it is necessary to count blood CD4 at patient with severe community-acquired pneumonia (CAP)?. , 2015, , .  |     | 0         |
| 20 | Can procalcitonin (PCT) be an indicator of viral severe community-acquired pneumonia (CAP) based on epidemics of influenza H<sub>1</sub>N<sub>1</sub>in season 2015-2016?. , 2016, , . |     | 0         |
| 21 | Plasma surfactant protein-D (SPD) concentration and severity of airflow limitation in COPD patients (pts). , 2016, , .   |     | 0         |
| 22 | Can procalcitonin or C-reactive protein predict supportive lung complications and ARDS at severe community-acquired pneumonia (CAP)?. , 2016, , .                                      |     | 0         |
| 23 | Changes in levels of inflammatory markers (procalcitonin, C-reactive protein) in pregnant with community-acquired pneumonia (CAP). , 2016, , .   |     | 0         |
| 24 | Levels of serum amyloid A (SAA) and C-reactive protein (CRP) in stable COPD patients and its relationship with disease severity. , 2017, , .   |     | 0         |
| 25 | Comparison of severity of clinical, functional signs of COPD with the frequency and severity of mental disorders. , 2017, , .  |     | 0         |
| 26 | Effects of nebivolol and ivabradine on myocardial ischemia in patients (pts) with COPD and stable angina during 24-hour ambulatory Holter ECG monitoring. , 2017, , .                  |     | 0         |
| 27 | Adherence to ICS in pregnant with infectious exacerbations of asthma (IEA). , 2017, , .  |     | 0         |
| 28 | Pneumonias in immunocompromised patients: improvement of treatment using the immunomodulator. ScienceRise: Medical Science, 2017, .  | 0.0 | 0         |
| 29 | Influence the phosphatidylcholine treatment program on surfactant protein D levels in hypertensive patients with community-acquired pneumonia. , 2018, , .                             |     | 0         |
| 30 | Is it connection between systemic inflammation and risk of thrombotic disorders (by Padua scale) in hospitalized patients with community-acquired pneumonia (CAP)?. , 2018, , .        |     | 0         |
| 31 | Thrombotic disorders (blood coagulation test and Padua Prediction Score for risk of lung) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5   |     | 0         |
| 32 | HEALTH RELATED QUALITY OF LIFE (HRQoL) AMONG PATIENTS WITH NON CYSTIC FIBROSIS BROCHIECTASIS (BE) IN STABLE PHASE. , 2018, , .   |     | 0         |